Physician profile
Steve K Jones
NPI 1407847734
$3,121.35
in general payments reported to CMS, 2019-2025
25 companies · $755 in 2025
The $755 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $241 · 2021: $447 · 2022: $433 · 2023: $299 · 2024: $695 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,749.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $621.31 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $460.09 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $398.85 | 2021-2025 | Caplyta |
| Stryker Corporation | $169.06 | 2022 | |
| Lilly USA, LLC | $167.00 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $165.57 | 2020-2024 | Repatha, Otezla |
| Sunovion Pharmaceuticals INC. | $150.64 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.02 | 2019-2025 | Jardiance, Synjardy |
| Atricure, INC. | $112.15 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.77 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $74.26 | 2024-2025 | Rexulti, Abilify Maintena |
| Pfizer INC. | $66.69 | 2024 | |
| Glaxosmithkline, LLC. | $66.60 | 2020-2025 | Shingrix, Arexvy, Bexsero |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.07 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $58.36 | 2023-2024 | Gardasil 9, Gardasil, Vaxelis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $47.54 | 2024-2025 | Lybalvi, Aristada |
| Eisai INC. | $45.39 | 2020 | |
| Verrica Pharmaceuticals INC. | $42.71 | 2024 | Ycanth |
| Exact Sciences Corporation | $42.63 | 2023-2025 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $38.42 | 2022 | |
| Gilead Sciences, INC. | $26.54 | 2019 | |
| Organon LLC | $24.64 | 2021 | |
| Genentech USA, INC. | $24.27 | 2020 | |
| Sanofi Pasteur INC. | $18.89 | 2021 | |
| Abbott Laboratories | $13.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.